Datroway (Datopotamab Deruxtecan)

Datopotamab deruxtecan is a medicine used to treat some kinds of advanced breast cancer and lung cancer. It is given as an infusion into a vein. It works like a guided missile: an antibody finds a marker on cancer cells and carries a chemotherapy drug right into them.

Brand names:Datroway
Medication

What people taking Datroway (Datopotamab Deruxtecan) report

Every report comes from a Lived member, sent anonymously.

Have you tried Datroway (Datopotamab Deruxtecan) for Breast Cancer?

NameHow it went

About Datroway (Datopotamab Deruxtecan)

What It's For

Datopotamab deruxtecan, sold as Datroway, is a cancer medicine given by infusion into a vein. It is used for adults with three kinds of advanced cancer, meaning cancer that has spread or cannot be removed with surgery. In triple-negative breast cancer (a type whose cells lack estrogen and progesterone receptors and do not overproduce HER2, a growth-signaling protein, so hormone and HER2 treatments do not work), it is an option, including as the first treatment for advanced disease, for people who cannot receive immunotherapy drugs known as PD-1 or PD-L1 inhibitors. In hormone receptor-positive, HER2-negative breast cancer, it is used after the cancer has progressed despite hormone-based treatment and chemotherapy given for advanced disease. In non-small cell lung cancer, it is used when the tumor carries a mutation in EGFR, the epidermal growth factor receptor gene (a change confirmed by testing tumor tissue or blood) and the cancer has already been treated with an EGFR-targeted drug and platinum chemotherapy. The lung cancer approval is an accelerated approval, based on how often and how long tumors shrank. A further trial is needed to confirm that it helps people live longer or better.

How It Works

Datroway is an antibody-drug conjugate, a combination of a targeting antibody and a chemotherapy drug joined by a chemical link. The antibody recognizes Trop-2, a protein found on the surface of many breast and lung cancer cells. Once the antibody attaches, the cell pulls the whole molecule inside, where the link is cut and the chemotherapy, called DXd, is released. DXd blocks topoisomerase I, an enzyme cells need to copy their DNA. Without it, the DNA is damaged and the cell dies.

Dosage & Administration

Datroway is given in an infusion center once every three weeks, at a dose based on body weight. The first infusion takes about 90 minutes and later ones about 30 minutes if earlier ones went well. Staff watch for infusion reactions during and after each dose, for at least an hour after the first two. Treatment usually continues for as long as the cancer stays under control and side effects are manageable. A missed dose is given as soon as possible, and the schedule is then reset to keep three weeks between doses. Several routines come with each cycle. Before every infusion, people receive medicines to prevent nausea and reactions, typically an antihistamine, acetaminophen and an anti-nausea drug. Holding ice chips or ice water in the mouth throughout the infusion helps protect the mouth lining, and a steroid-containing mouthwash used four times a day helps prevent mouth sores. Preservative-free lubricating eye drops are used at least four times a day, and contact lenses should be avoided unless an eye specialist says otherwise. An eye exam is done before starting and repeated regularly during treatment.

Side Effects

Mouth sores and inflammation (stomatitis) are the most common problem, affecting most people at some point, often within the first month. Nausea, tiredness, hair loss, constipation, vomiting, reduced appetite and rash are also common. Eye problems occur in more than a third of people, most often dry, gritty or watery eyes and inflammation of the cornea (keratitis), the clear front surface of the eye. Mouth and eye symptoms are worth reporting early, because the team can adjust treatment, pause doses or lower the dose before they become severe. The most serious risk is lung inflammation, called interstitial lung disease or pneumonitis, which can be severe and has been fatal in a small number of people. Contact the care team right away about a new or worsening cough, shortness of breath or fever, even if it seems minor. If lung inflammation is suspected, treatment is paused and steroids are usually started; confirmed moderate or worse inflammation means stopping Datroway for good.

Interactions & Warnings

Datroway can harm a developing baby. A pregnancy test is done before starting. Women who could become pregnant should use effective birth control during treatment and for 7 months after the last dose, and men with partners who could become pregnant should use effective birth control for 4 months after. Anyone who becomes pregnant or suspects a pregnancy should tell the care team. Breastfeeding is not recommended during treatment or for 1 month after the last dose. The medicine may also reduce fertility in both men and women, which is worth raising before treatment if future children matter. People who have had lung inflammation that needed steroid treatment, or significant disease of the cornea, were not included in the main studies, so these histories call for a careful discussion of risks. The care team should also know about liver disease and all other medicines and supplements being taken.

What to Expect

Treatment follows a three-week rhythm of infusion, recovery and daily mouth and eye care. Scans are repeated at intervals to see whether the cancer is shrinking, stable or growing, and that result guides whether to continue. In a large trial of people with triple-negative breast cancer starting treatment for advanced disease, Datroway roughly doubled the median time before the cancer grew compared with standard chemotherapy (about 11 months versus about 6) and extended median survival by about five months. In hormone receptor-positive breast cancer, it delayed cancer growth by a median of about two months compared with chemotherapy but did not help people live longer. In EGFR-mutated lung cancer, tumors shrank substantially in about 45 percent of people, and those responses lasted a median of about six and a half months. These are averages; individual results vary widely. In the trials, roughly a quarter of people needed a lower dose at some point, most often because of mouth sores. Regular eye checks continue throughout, and another eye exam is done when treatment ends.

Questions to Ask Your Doctor

  1. 1.Why is Datroway recommended for my cancer now, and what other treatments could I consider instead?
  2. 2.What benefit is realistic for someone in my situation, and how will we know whether it is working?
  3. 3.How should I use the mouthwash, ice chips and eye drops, and what mouth or eye symptoms should I report?
  4. 4.Does my lung or eye history make Datroway riskier for me, and how will you watch for lung inflammation?
  5. 5.What birth control do I need, for how long, and should I consider fertility preservation before starting?

Last reviewed • Oct 2026

Educational content, not medical advice.